Biomedical Engineering Reference
In-Depth Information
References
[1] Pouton CW, Wagstaff KM, Roth DM, Moseley GW, Jans DA. Targeted delivery to the
nucleus. Adv Drug Delivery Rev 2007;59:698-717.
[2] Anderson WF. Human gene therapy. Nature 1998;392:25-30.
[3] Romano G, Pacilio C, Giordano A. Gene transfer technology in therapy: current applica-
tions and future goals. Stem Cells 1999;17:191-202.
[4] Howrey RP, Alfondi ME, Phillips KL, Wilson L, Rooney B, Lan N, et al. An
in vitro
system for efficiently evaluating gene therapy approaches to hemoglobinopathies. Gene
Ther 2000;7:215-25.
[5] Kim CK, Haider KH, Lim SJ. Gene medicine: a new field of molecular medicine. Arch
Pharmacol Res 2001;24:1-15.
[6] Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. Gene therapeutic
approaches—transfer
in vivo
. Adv Drug Delivery Rev 2006;58:243-58.
[7] Verma IM, Somia N. Gene therapy—promises, problems and prospects. Nature 1997;
389:239-42.
[8] Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, et al.
T-Lymphocyte-directed gene therapy for ADA deficiency SCID: initial trial results after
4 years. Science 1995;270:475-80.
[9] Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treat-
ment of cancers. Hum Gene Ther 2005;16:1016-27.
[10] Jia H. Gene therapy finds welcoming environment in China. Nat Med 2006;12:263-64.
[11] Marshall E. Clinical trials: gene therapy death prompts review of adenovirus vector. Science
1999;286:2244-5.
[12] Cavazzana-Calvo M, Hacein-Bey S, De Saint Basile G, Gross F, Yvon E, Nusbaum P,
et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
Science 2000;288:669-72.
[13]
http://
www.wiley.co.uk/genmed/clinical/
.
Dated 20 April 2010.
[14] Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer
into mouse muscle
in vivo
. Science 1990;247:1465-8.
[15] Srivastava IK, Liu MA. Gene vaccines. Ann Intern Med 2003;138:550-9.
[16] Belakova J, Horynova M, Krupka M, Weigl E, Raska M. DNA vaccines: are they still just
a powerful tool for the future? Arch Immunol Ther Exp 2007;55:387-98.
[17] Donnelly JJ, Ulmer JB, Liu MA. Protective efficacy of intramuscular immunization with
naked DNA. Ann NY Acad Sci 1995;772:40-6.
[18] Allen TM, Vogel TU, Fuller DH, Mothe BR, Steffen S, Boyson JE, et al. Induction of
AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes
from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara
boost regimen. J Immunol 2000;164:4968-78.
[19] Barouch DH, Craiu A, Santra S, Egan MA, Schmitz JE, Kuroda MJ, et al. Elicitation
of high-frequency cytotoxic T-lymphocyte responses against both dominant and sub-
dominant simian-human immunodeficiency virus epitopes by DNA vaccination of rhesus
monkeys. J Virol 2001;75:2462-7.
[20] Wang R, Doolan DL, Hedstrom RC, Coonan KM, Charoenvit Y, Jones TR, et al.
Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vac-
cine. Science 1998;282:476-80.
[21] Yankauckas MA, Morrow JE, Parker SE, Abai A, Rhodes GH, Dwarki VJ, et al. Long-
term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular
injection of plasmid DNA containing NP gene. DNA Cell Biol 1993;12:771-6.
Search WWH ::
Custom Search